[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608267":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":57,"collaborators":60,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":68,"sex":74,"minAge":75,"maxAge":20,"enrollmentInfo":76,"targetDuration":20,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":87,"overallStatus":29,"whyStopped":20,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Massachusetts General Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"All participants","EXPERIMENTAL","All participants will receive long-acting injectable cabotegravir and a suite of support services, including PrEP navigation, transportation assistance, and financial incentives.",[13],"Drug: APRETUDE (cabotegravir)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","APRETUDE (cabotegravir)","All participants will be prescribed APRETUDE based on APRETUDE's FDA approved indication, which is sexual risk of HIV transmission.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Suzanne McCluskey, MD, MSc","CONTACT","617-726-9488","SMCCLUSKEY@MGH.HARVARD.EDU",[28,45],{"facility":5,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"RECRUITING","Boston","Massachusetts","02114","United States","US",{"type":36,"coordinates":37},"Point",[38,39],-71.05977,42.35843,{"lat":39,"lon":38},[42,43],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"name":23,"role":44,"phone":20,"phoneExt":20,"email":20},"PRINCIPAL_INVESTIGATOR",{"facility":46,"status":29,"city":30,"state":31,"zip":47,"country":33,"countryCode":34,"cosmosGeoPoint":48,"geoPoint":50,"contacts":51},"Fenway Health","02215",{"type":36,"coordinates":49},[38,39],{"lat":39,"lon":38},[52,56],{"name":53,"role":24,"phone":54,"phoneExt":20,"email":55},"Julia Fleming, MD, MHS","857-313-6984","JFleming@fenwayhealth.org",{"name":53,"role":44,"phone":20,"phoneExt":20,"email":20},{"type":44,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Suzanne McCluskey","Assistant Professor",[61,64],{"name":62,"class":63},"ViiV Healthcare","INDUSTRY",{"name":65,"class":6},"Fenway Community Health","100608267","phase-4-long-acting-cabotegravir-injectable-pre-exposure-prophylaxis-for-people-who-inject-drugs-100608267",false,"NCT07199335","Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs","A Multi-Center Assessment of an Intervention to Provide Long-Acting Cabotegravir Injectable Pre-Exposure Prophylaxis to People Who Inject Drugs","ASCEND","Inclusion Criteria:\n\n* HIV Ab\u002FAg test (lab-based or rapid) negative at time of enrollment\n* ≥18 years old\n* Able to provide informed consent\n* Have injected non-prescribed drugs within the past 6 months\n* No prior history of receiving cabotegravir (Note: prior or active use of non-CAB PrEP (\\[FTC\u002FTDF or FTC\u002FTAF\\]) at screening is allowed, but participant will need to indicate that they prefer to switch to injectable PrEP).\n* PrEP provider deems cabotegravir use to be appropriate per the applicable prescribing information prior to enrollment in the study.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding people. Should a participant become pregnant, the treating physician will discuss with the participant whether to continue study medication, taking into consideration the risks and benefits of continuing cabotegravir compared with the risk of switching to an alternative recommended PrEP regimen.\n* Has not had vaginal or anal sex in the past 6 months\n* HIV indeterminate or positive test result during screening and prior to initiation of CAB PrEP\n* Already diagnosed with HIV\n* Taking any of the following medications: Carbamazepine, Rifampin, Oxcarbazepine, Rifapentine, Phenobarbital, Phenytoin","ALL","18 Years",{"count":77,"type":78},100,"ESTIMATED","INTERVENTIONAL",[81],"PHASE4","The goal of this study is to determine the feasibility and impact of delivering long-acting injectable cabotegravir HIV pre-exposure prophylaxis and suite of support services to adults who inject non-prescription drugs who are risk for HIV through known sexual risk.",[84,85,86],"HIV","Substance Use Disorder (SUD)","Injection Drug Use",[84,88,89,90,91,92,93,94],"Substance use","pre-exposure prophylaxis","cabotegravir","long-acting cabotegravir","PrEP","implementation science","PrEP navigator","2026-03-17",{"date":97,"type":98},"2026-03-19","ACTUAL",{"date":100,"type":98},"2026-02-24",{"date":102,"type":78},"2028-12",{"name":5,"class":6},2]